The degree of patient adherence is increasingly recognized to be a key factor in the success of highly active antiretroviral therapy (HAART). HAART regimens are also among the most complex ever prescribed and low adherence is directly related to treatment complexity. Physicians prescribing HAART need to make adherence a priority both in clinical practice and in the design and interpretation of clinical trials if HAART really is to succeed in the long term.
References
1.
CarpenterC.C., FischlM.A., HammerS.M., HirschM.S., JacobsonD.M., KatzensteinD.A., MontanerJ.S., RichmanD.D., SangM.S., SchooleyR.T., ThompsonM.A., VellaS., YeniP.G., & VolberdingP.A.Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel. Journal of the American Medical Association1998; 280: 78–86.
2.
VanhoveG.F., SchapiroJ.M., WintersM.M., MeriganT.C., & BlacshkeT.F.Patient compliance and drug failure in protease inhibitor monotherapy (letter). Journal of the American Medical Association1996; 276: 1955–1956.
3.
HaynesR.B.Introduction. In Compliance in health care., 1979 Edited by HaynesR.B., TaylorD.W., & SackettD.L.Baltimore: Johns Hopkins University Press.
4.
MyersL.B., & MidenceK.Concepts and issues in adherence. In Adherence to treatment in medical conditions, 1998. Edited by MyersL.B., & MidenceK.Amsterdam: Harwood Academic Publishers.
5.
PatersonD., SwindellsS., MolirJ., BresterM., VergisE., SquierC., WagenerM., & SinghN.How much adherence is enough? A preparative study of adherence to protease inhibitor therapy using MEMSCaps.6th Conference on Retroviruses and Opportunistic Infections, 31 January–4 February, 1999, Chicago, Illinois, USA. Abstract 92.
6.
SackettD.L., & SnowJ.C.The magnitude of adherence and non-adherence. In Compliance in health care, 1979, pp. 11–22. Edited by HaynesR.B., TaylorD.W., & SackettD.L.Baltimore: Johns Hopkins University Press.
7.
SinghN., SquierC., SivekC., WagenerM., NguyenM.H., & YuV.L.Determinants of compliance with antiretroviral therapy in patients with human immunodeficiency virus: prospective assessment with implications for enhancing compliance. AIDS Care1996; 8: 261–269.
8.
SametJ.H., LibmanH., StegerK.A., DhawanR.K., ChenJ., & ShevitzA.H., Dewees-DunkR., LevensonS., KufeD., CravenD.E.Compliance with zidovudine therapy in patients infected with human immunodeficiency virus, type 1: a cross-sectional study in a municipal hospital clinic. American Journal of Medicine1992; 92: 495–502.
9.
EldredL.J., WuA.M., ChaissonR.E., & MooreR.D.Adherence to antiretroviral and Pneumocystis prophylaxis in HIV disease. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology1998; 18: 117–125.
10.
MumaR.D., RossM.W., ParcellG.S., & PollardR.B.Zidovudine adherence among individuals with HIV infection. AIDS Care1995; 7: 439–447.
11.
KastrissiosH., SuarezJ-R, KatzensteinD., GirardP., SheinerL.B., & BlashkeT.F.Characterising patterns of drug-taking behaviour with a multiple drug regimen in an AIDS clinical trial. AIDS1998; 12: 2295–2303.
12.
HechtF.M., ColfaxG., SwansonM., & ChesneyM.A.Adherence and effectiveness of protease inhibitors in clinical practice.5th Conference on Retroviruses and Opportunistic Infections. 1–5 February 1998, Chicago, Illinois, USA. Abstract 151.
13.
ChesneyM.A., & HechtF.M.Adherence to HIV antiretroviral therapy: an essential element to understanding treatment effect.2nd European Conference on the Methods and Results of Social and Behavioural Research on AIDS. 12–15 January 1998, Paris, France.
14.
WalshJ.C., DaltonM., & GazzardB.G.Adherence to combination antiretroviral therapy assessed by anonymous patient self report. AIDS1998; 12: 2361–2362.
15.
MehtaS., MooreR.D., & GrahamN.M.H.Potential factors affecting adherence with HIV therapy. AIDS1997; 11: 1665–1670.
16.
HomeR., & WeinmanJ.Predicting treatment adherence; an overview of theoretical models. In Adherence to treatment in medical conditions, 1998. Edited by MyersL.B., & MidenceK.Amsterdam: Harwood Academic Publishers.
17.
LeventhalH., DiefenbachM., & LeventhalE.A.Illness cognition; using common sense to understand treatment adherence and affect condition interactions. Cognitive Therapy Research1992; 16: 143–163.
18.
Concorde Coordinating Committee.Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom free HIV infection. Lancet1994; 343: 871–880.
19.
Lipid Research Clinics Program.Lipid Research Clinics Coronary Primary Prevention Trial results II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. Journal of the American Medical Association1984; 251: 365–374.
